New York, March 2, 2026, 18:05 EST — After-hours
- Eli Lilly (LLY) dropped roughly 3.2%, recently trading at $1,017.97.
- The company is eyeing an FDA decision in April on orforglipron, its oral obesity drug, and says a launch could come as soon as the second quarter.
- U.S. drug-pricing scrutiny is on the radar for investors, as is the growing rivalry in the weight-loss drug space.
Shares of Eli Lilly and Company (LLY) slid 3.2% in after-hours action Monday, changing hands at $1,017.97. The stock had already dropped during the regular session.
The stock reacted as the drugmaker urged investors to turn their attention to its upcoming obesity contender, orforglipron. That’s a once-daily pill designed to hit GLP-1—a gut hormone tied to appetite and blood sugar control. For Lilly, valuation is now bound up with how quickly it can ramp up weight-loss drugs and hold onto pricing power.
Payers and lawmakers want drug costs down, but appetite for weight-loss meds isn’t fading. Just a slight tweak in coverage or a price cut can sway profit outlooks.
Lucas Montarce, Chief Financial Officer, told the TD Cowen healthcare conference that Lilly’s orforglipron might hit the U.S. market “as early as Q2,” provided the FDA gives the green light in April. Montarce said shipping could begin roughly a week after approval. He also noted ongoing talks with pharmacy benefit managers — those negotiating coverage and rebates — about securing access. 1
Lilly shares ended the day off 3.23%, underperforming a flat S&P 500 and putting the stock roughly 10% under its Jan. 8 52-week peak, according to MarketWatch. Trading volume came in close to the recent norm, the outlet added. 2
Competitive pressures aren’t letting up, and price jitters persist. Novo Nordisk announced last week it plans to drop U.S. list prices for Ozempic and Wegovy to $675 a month starting Jan. 1, 2027. Citi’s Geoffrey Meacham flagged that the cut would probably affect just a slim segment of new prescriptions, mostly missing the cash-pay crowd who foot the bill themselves. Bernstein analyst Courtney Breen, for her part, dismissed the move as “not the beginning of a price war.” 3
The Trump administration is pressing smaller drugmakers to hammer out lower Medicaid prices, Reuters said, after 16 major firms, Lilly among them, agreed to similar terms. The CMS has pushed back the application deadline for its new payment model to April 30 and set April 1 for kicking off talks with interested manufacturers. According to Innovation Center director Abe Sutton, the extension aims to let more companies join in and “lower costs to the Medicaid program.” 4
Exactly how those moves ripple through the obesity market is what investors are puzzling over, especially since rebates can leave a big gap between list and net prices. PBMs and insurers hold the cards on preferred drug placement, shaping patient access well ahead of any visible list price shifts.
Lilly still faces tolerability hurdles. In a diabetes trial comparing orforglipron to Novo’s oral semaglutide, released last week, more patients on the highest dose of Lilly’s drug dropped out or reported stomach issues. Kenneth Custer, the company’s cardiometabolic president, called it “a trade-off” he expects patients will accept for stronger glucose and weight reductions. 5
Right now, traders want to see if the FDA review schedule holds—any hint of a delay gets attention. The focus is also on whether Lilly can secure wide insurance coverage before launch. If rollout happens quickly, it’ll pressure Lilly’s production and logistics, and test insurers’ appetite for footing the bill on yet another costly obesity treatment.
Investors are now watching for two things: an FDA ruling set for April and Lilly’s upcoming Q1 earnings call, slated for April 30. 6
